JDTic

JDTic
(IUPAC) ime
	(3R)-7-hydroxy- N-((1S)-1[(3R,4R)-4- (3-hydroxyphenyl)- 3,4-dimethylpiperidin- 1-yl]methyl 2-methylpropyl)- 1,2,3,4-tetrahydroisoquinoline- 3-carboxamide
Klinički podaci
Identifikatori
CAS broj	361444-66-8 ; 785835-79-2 (hidrohlorid)
ATC kod	?
PubChem	9956146
Hemijski podaci
Formula	C28H39N3O3
Mol. masa	465.626 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C28H39N3O3/c1-18(2)26(30-27(34)25-13-20-8-9-24(33)12-21(20)15-29-25)17-31-11-10-28(4,19(3)16-31)22-6-5-7-23(32)14-22/h5-9,12,14,18-19,25-26,29,32-33H,10-11,13,15-17H2,1-4H3,(H,30,34)/t19-,25+,26+,28+/m0/s1 ; Key: ZLVXBBHTMQJRSX-VMGNSXQWSA-N
Sinonimi	JDTic
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

JDTic je lek, koji je visoko selektivni κ-opioidni antagonist. On blokira taj receptor bez vršenja uticaja na μ- ili δ- opioidne receptore.^[3] On je derivat 4-fenilpiperidina, koji je u nekoj meri strukturno srodan sa analgeticima kao što su meperidin i ketobemidon, i bliže sa mi opioidnim antagonistom alvimopanom. On se strukturno razlikuje od drugih kapa antagonist,a kao što je norbinaltorfimin.^[4]^[5]

On ima veoma dugo vreme dejstva, sa efektima na životinjama primetnim do nekoliko nedelja nakon administracije jedne doze,^[6] mada njegovo vezivanje za kapa opioidni receptor nije nepovratno i njegovi dugotrajno dejstvo je umesto toga uzrokovano promenama aktivnosti c-Jun N-terminalne kinaze.^[7] Iz životinjska ispitivanja proizilazi da on može da proizvede antidepresantske i anksioloitičke efekte,^[8] kao i da može da ima primenu u lečenju adikcije na kokain i morfin.^[9]^[10]

Vidi još uredi

Norbinaltorfimin

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, Cantrell BE, Zimmerman DM, Carroll FI. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. Journal of Medicinal Chemistry. 2001 Aug 16;44(17):2687-90. PMID 11495579
↑ Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI. Identification of (3R)-7-hydroxy- N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl- 1-piperidinyl]methyl]- 2-methylpropyl)- 1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. Journal of Medicinal Chemistry. 2003 Jul 3;46(14):3127-37. PMID 12825951
↑ Cai TB, Zou Z, Thomas JB, Brieaddy L, Navarro HA, Carroll FI. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl- 1-piperidinyl]methyl 2-methylpropyl)- 1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide (JDTic). Journal of Medicinal Chemistry. 2008 Mar 27;51(6):1849-60. PMID 18307295
↑ Carroll FI, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. European Journal of Pharmacology. 2004 Oct 6;501(1-3):111-9. PMID 15464069
↑ Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. Journal of Biological Chemistry. 2007 Oct 12;282(41):29803-11. DOI 10.1074/jbc.M705540200 PMID 17702750
↑ Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. Journal of Pharmacology and Experimental Therapeutics. 2007 Dec;323(3):838-45. PMID 17823306
↑ Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berlin). 2005 Nov;183(1):118-26. DOI 10.1007/s00213-005-0167-4 PMID 16184376
↑ Carroll FI, Harris LS, Aceto MD. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. European Journal of Pharmacology. 2005 Nov 7;524(1-3):89-94. PMID 16236279

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, Cantrell BE, Zimmerman DM, Carroll FI. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. Journal of Medicinal Chemistry. 2001 Aug 16;44(17):2687-90. PMID 11495579

[4] Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI. Identification of (3R)-7-hydroxy- N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl- 1-piperidinyl]methyl]- 2-methylpropyl)- 1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. Journal of Medicinal Chemistry. 2003 Jul 3;46(14):3127-37. PMID 12825951

[5] Cai TB, Zou Z, Thomas JB, Brieaddy L, Navarro HA, Carroll FI. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl- 1-piperidinyl]methyl 2-methylpropyl)- 1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide (JDTic). Journal of Medicinal Chemistry. 2008 Mar 27;51(6):1849-60. PMID 18307295

[6] Carroll FI, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. European Journal of Pharmacology. 2004 Oct 6;501(1-3):111-9. PMID 15464069

[7] Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. Journal of Biological Chemistry. 2007 Oct 12;282(41):29803-11. DOI 10.1074/jbc.M705540200 PMID 17702750

[8] Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. Journal of Pharmacology and Experimental Therapeutics. 2007 Dec;323(3):838-45. PMID 17823306

[9] Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berlin). 2005 Nov;183(1):118-26. DOI 10.1007/s00213-005-0167-4 PMID 16184376

[10] Carroll FI, Harris LS, Aceto MD. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. European Journal of Pharmacology. 2005 Nov 7;524(1-3):89-94. PMID 16236279

[3]

[4]

[5]

[1]

[2]

[6]

[7]

[8]

[9]

[10]